9-(β-L-arabinofuranosyl)adenine | 62560-97-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-(β-L-arabinofuranosyl)adenine
• 英文别名: (2S,3R,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol；(2S,3R,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 62560-97-8
• 化学式: C₁₀H₁₃N₅O₄
• 分子量: 267.244
• InChiKey: OIRDTQYFTABQOQ-CMEPRQAFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  9-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine 在 二氯乙酸 、 sodium tetrahydroborate 、 氨 、 一水合肼 、 二甲基亚砜 、 N,N'-二环己基碳二亚胺 作用下， 以 吡啶 、 甲醇 、 乙醇 、 溶剂黄146 、 苯 为溶剂， 反应 51.0h， 生成 9-(β-L-arabinofuranosyl)adenine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 9-(β-L-Arabinofuranosyl)Adenine

  摘要：

  For the first time, the stereospecific synthesis of 9-(beta-L-arabinofuranosyl) adenine was carried out. Unfortunately, and unlike its "natural" D-counterpart Vidarabine, this L-enantiomer did not show significant activity when evaluated against a broad range of viruses.

  DOI：

  10.1080/07328319908044620

文献信息

• [EN] SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS<br/>[FR] DIHYDROIMIDAZOPYRIDINEDIONES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE MKNK1 ET DE MKNK2
  申请人：BAYER PHARMA AG

  公开号：WO2018134148A1

  公开（公告）日：2018-07-26

  The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (A) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（A）所描述和定义的取代二氢咪唑吡啶二酮化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和复合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增殖、血管生成障碍、炎症性疾病或与炎症性疼痛相关的疾病的药物组合物，作为单一药剂或与其他活性成分结合使用。
• [EN] L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS<br/>[FR] NUCLEOSIDES - L POUR LE TRAITEMENT DES VIRUS DE L'HEPATITE B ET EPSTEIN-BAR
  申请人：UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  公开号：WO1995020595A1

  公开（公告）日：1995-08-03

  (EN) A method for the treatment of a host, and in particular, a human, infected with HBV or EBV is provided that includes administering an HBV- or EBV- treatment amount of an L-nucleoside of formula(I) wherein R is a purine or pyrimidine base. In one preferred embodiment, the active compound is 2'-fluoro-5-methyl-$g(b)-L-arabinofuranosyluridine (also referred to as L-FMAU). This compound is a potent antiviral agent against HBV and EBV and exhibits low cytotoxicity. Other specific examples of active compounds include N1-(2'-deoxy-2'-fluoro-$g(b)-L-arabinofuranosyl)-5-ethyluracil, N1-(2'-deoxy-2'-fluoro-$g(b)-L-arabinofuranosyl)-5-iodocytosine), and N1-(2'-deoxy-2'-fluoro-$g(b)-L-arabinofuranosyl)-5-iodouracil.(FR) Méthode de traitement d'un hôte (humain en particulier) infecté par le VHB ou le VEB et consistant à lui administrer une dose adéquate d'un nucléoside-L de formule (I) dans laquelle R est une base purique ou pyrimidique. Dans un mode préféré de réalisation, le principe actif est une 2'-fluoro-méthyl-$g(b)-L-arabinofuranosyluridine (L-FMAU), composé antiviral puissant contre le VHB et le VEB, présentant une faible cytotoxicité. D'autres exemples spécifiques de composés actifs comprennent le N1-(2'-désoxy-2'-fluoro-$g(b)-L-arabinofuranosyl)-5-éthyluracyl; le N1-(2'-désoxy-2'-fluoro-$g(b)-L-arabinofuranosyl)-5-iodocytosine; et le N1-(2'-déoxy-2'-fluoro-$g(b)-L-arabinofuranosyl)-5-iodouracil.

  一种治疗宿主，特别是人类感染HBV或EBV的方法，包括给予HBV或EBV治疗剂量的L-核苷，其化学式为(I)，其中R为嘌呤或嘧啶碱基。在一个首选实施例中，活性化合物是2'-氟-5-甲基-$g(b)-L-阿拉伯核糖苷尿嘧啶（也称为L-FMAU）。该化合物是一种强效的抗HBV和EBV病毒剂，且表现出低细胞毒性。其他特定的活性化合物的例子包括N1-(2'-脱氧-2'-氟-$g(b)-L-阿拉伯核糖苷)-5-乙基尿嘧啶，N1-(2'-脱氧-2'-氟-$g(b)-L-阿拉伯核糖苷)-5-碘胞嘧啶和N1-(2'-脱氧-2'-氟-$g(b)-L-阿拉伯核糖苷)-5-碘尿嘧啶。
• Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US11311520B2

  公开（公告）日：2022-04-26

  The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

  本发明涉及本文所描述和定义的通式（I）的取代二氢咪唑吡啶二酮化合物，涉及制备所述化合物的方法，涉及用于制备所述化合物的中间体化合物，涉及包含所述化合物的药物组合物和组合物，还涉及使用所述化合物制造药物组合物，用于治疗或预防疾病，特别是过度增殖性疾病、血管生成障碍、炎症性疾病或与炎性疼痛相关的疾病，可作为单独制剂或与其他活性成分组合使用。
• 8-Substituted Adenine β-D-Xylofuranosides and α-L-Arabinofuranosides
  作者：Janis Jansons、Yuris Maurinsh、Margeris Lidaks

  DOI：10.1080/15257779508009752

  日期：1995.10

  9-(beta-D-Xylofuranosyl)adenine and 9-(alpha-L-arabinofuranosyl)adenine have been modified to give a series of gr-amino-substituted nucleosides. Convenient methods of halogenation of these nucleosides and reactions of 8-halogenated nucleosides with various amines are described. No significant cytotoxic or antiviral activity was found.
• L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS
  申请人：THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  公开号：EP0748330B1

  公开（公告）日：2003-04-02